The U.S. Department of Justice (DOJ) took a major step in federal cannabis policy, triggering immediate reactions across the stock market. By placing FDA-approved marijuana products and state-licensed medical cannabis in Schedule III of the Controlled Substances Act, the agency has introduced a policy shift that investors have long anticipated.
The decision signals both near-term regulatory relief and the potential for broader reform. With a key hearing set for June 29, 2026, markets are now pricing in not just what has changed, but what could come next.
What the Schedule III Shift Means for Cannabis Stocks
The reclassification applies to two specific segments:
- FDA-approved marijuana-derived products
- Dannabis products distributed under qualifying state-issued medical licenses
These products move from Schedule I, reserved for substances with no accepted medical use, into Schedule III, a category that allows regulated medical use and carries fewer restrictions, creating meaningful financial implications for publicly traded operators tied to medical markets.
Companies operating within state-licensed medical programs may now deduct standard business expenses at the federal level. Under the previous framework, Section 280E prevented these deductions, significantly compressing margins across the industry. Removing that burden could improve cash flow, profitability, and ultimately valuations.
The shift also opens the door to expanded research, as lower regulatory barriers may accelerate clinical trials and product development, benefiting companies focused on pharmaceutical-grade cannabis or FDA pathways.
Market Reaction: Rally Fades as Investors Reassess
Cannabis stocks reacted quickly to the announcement, with shares of Aurora Cannabis, Tilray, and Canopy Growth rising sharply in pre-market trading. Cannabis-focused ETFs also posted gains as investors priced in the tax and regulatory upside.
However, the rally lost momentum as the trading session progressed. Many stocks reversed into the red, reflecting a more cautious market interpretation.
This pattern suggests that much of the optimism had already been priced in. Investors had anticipated some form of rescheduling, and the limited scope, focused on medical and FDA-approved products, fell short of broader legalization expectations.
June 2026 Hearing: The Real Catalyst for the Sector
While the current reclassification matters, investors are now focused on the next major milestone: the administrative hearing set to begin on June 29, 2026.
This process will evaluate whether marijuana should be broadly moved from Schedule I to Schedule III under federal law. A full rescheduling could apply across the wider cannabis market, including operators involved in both medical and recreational segments, representing a high-impact catalyst with several potential outcomes:
- Broader application of standard tax deductions could significantly boost earnings across the sector
- Lower regulatory risk may attract institutional investors and reduce financing costs
- Greater legal clarity could accelerate M&A activity among operators
- Easier research pathways may support new drug development and differentiated offerings
Still, political opposition and regulatory complexity could slow or limit the scope of reform, making the hearing a key risk event as much as an opportunity.
Policy Context and Market Implications
The DOJ’s move follows a December 2025 executive order directing agencies to accelerate cannabis research and policy review.
Today, 40 states operate medical marijuana programs, and many also allow recreational use. By moving state-licensed medical cannabis into Schedule III, the federal government acknowledges this reality, but stops short of full alignment.
Industry groups have framed the decision as a breakthrough, but critics argue that the change may disproportionately benefit larger operators and send mixed signals about regulatory direction.
What Investors Should Watch Next
The months leading up to the June hearing will be critical for cannabis equities. The current reclassification provides incremental relief, but the broader rescheduling decision will likely define the next phase of growth (or stagnation) for the sector.
Key signals to monitor include:
- Updates and testimony from the June 2026 hearing process
- Regulatory guidance on how Schedule III rules will be implemented
- Market reactions to timeline changes or delays
- Legislative responses at both federal and state levels
Investors must balance short-term volatility with long-term positioning as the regulatory landscape continues to evolve.
Rita Ferreira
Rita is a seasoned writer with over five years of experience, having worked with globally renowned platforms, including Forbes and Miister CBD. Her deep knowledge of hemp-related businesses and passion for delivering accurate and concise information distinguish her in the industry. Rita's contributions empower individuals and companies to navigate the complexities of the cannabis world, and her work remains a valuable resource for those seeking a deeper understanding of its potential.
